Form 4: Camp4 Therapeutics Corp: CFO Acquires Stock Options

Camp4 Therapeutics Corp. reports that Chief Financial Officer Kelly Gold acquired 215,000 stock options with an exercise price of $4.46.

Summary

• Kelly Gold, Chief Financial Officer of Camp4 Therapeutics Corp., acquired 215,000 stock options on April 1, 2026.
• The stock options have an exercise price of $4.46 per share.
• These options are exercisable and expire on March 31, 2036.
• The underlying shares vest in equal monthly installments over four years from the grant date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard executive compensation action rather than a significant financial event or strategic shift.

Positives

• The Chief Financial Officer's acquisition of stock options signals confidence in the company's future prospects.
• The grant of options aligns the CFO's incentives with shareholder value creation.
• The exercise price of $4.46 suggests a valuation at the time of grant that may offer upside potential.

Risks

• The value of the stock options is contingent on the future performance of Camp4 Therapeutics Corp.'s stock price.
• If the company's stock price does not exceed the exercise price of $4.46, the options may expire worthless.
• Vesting over four years means the full benefit of the options is realized over an extended period, subject to continued employment.

Future Outlook

The vesting schedule of the stock options over four years suggests a long-term outlook for the company's performance, as the full benefit is tied to sustained employment and potential stock appreciation.

Industry Context

StockSavvy.ai notes that the issuance of stock options to key executives like the CFO is a common practice in the biotechnology and pharmaceutical sectors to attract and retain talent and to align executive interests with those of shareholders, especially in companies focused on research and development where long-term value creation is paramount.

Stakeholder Impact

• Shareholders: The acquisition of options by the CFO may be viewed positively as a sign of management confidence, potentially aligning executive interests with shareholder value.
• Employees: This filing is primarily related to executive compensation and has no direct stated impact on other employees.
• Management: The CFO has been granted an incentive tied to the company's stock performance.

Next Steps

• The stock options will vest over a four-year period.
• The CFO may exercise the vested options at $4.46 per share until the expiration date of March 31, 2036.

Key Dates

Keywords

stock options, Camp4 Therapeutics Corp, CFO, insider trading, equity compensation, SEC Form 4, beneficial ownership